About UsCommitted to innovating a new generation of neuroscience medicines that set new standards of care

Vistagen is developing an innovative pipeline of neuroscience medications with the potential to establish new standards of care in the treatment of multiple psychiatric and neurological disorders that disrupt the lives of tens of millions of people in the U.S. and around the world.

Our VisionStriving for a world no longer gripped by anxiety and depression

Vistagen’s core goal is to radically improve mental health and well-being worldwide. In developing safe and effective treatments, we aim to improve mental health care with better outcomes for patients, caregivers, advocates and communities.

Large Unmet Mental Health Care Needs in Anxiety and Depression

25 Million1

Americans suffer from Social Anxiety Disorder

19.4 Million2

Adults in the US had at least one major Depressive Episode

264 Million3

People World-wide suffer from Depression

1. Kantar Health. Nov 2021. National Health and Wellness Survey (NHWS), 2021. [US]. Malvern, PA. | 2. Substance Abuse and Mental Health Services Administration, 2020 | 3. World Health Organization

Pipeline Vistagen Products in Development

For Anxiety Disorders

Fasedienol is a first-in-class, rapid-onset investigational pherine nasal spray designed with potential to treat multiple anxiety disorders without the side effects and safety concerns associated with currently prescribed anti-anxiety products.

For Depression

Itruvone is a rapid-onset investigational pherine nasal spray designed for potential stand-alone treatment for major depressive disorder and other neuropsychiatric indications involving depression.

For Menopausal Hot Flashes, Premenstrual Dysphoric Disorder and Migraine

PH80, an investigational pherine, is a potential treatment for the acute management of vasomotor symptoms (hot flashes) due to menopause, acute management of symptoms of premenstrual dysphoric disorder and acute treatment of migraine.

For Improvement of Cognition

PH15 is an investigational pherine designed as a potential new treatment for many disorders that lead to sleep deprivation and ensuing fatigue and cognitive impairment.

For Appetite-related Disorders

PH284 is an investigational pherine with potential to treat appetite related disorders such as Cachexia (Wasting Syndrome), a serious but under recognized consequence of many chronic diseases and advanced cancer.

For CNS Diseases & Disorders

AV-101 (4-Cl-KYN) is an investigational oral prodrug of 7-Cl-KYNA, a full antagonist of the glycine site of the NMDA receptor, with potential to treat multiple CNS diseases and disorders.